COMPASS Pathways Sees Unusually High Options Volume (NASDAQ:CMPS)

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) saw some unusual options trading activity on Tuesday. Traders purchased 10,094 call options on the company. This represents an increase of 290% compared to the typical volume of 2,587 call options.

Key Stories Impacting COMPASS Pathways

Here are the key news stories impacting COMPASS Pathways this week:

• Positive Sentiment: COMP360 met the primary endpoint in a late‑stage (Phase 3) study, driving optimism about regulatory and commercial prospects for the psilocybin therapy. This is the main catalyst for the rally. Compass Pathways’ depression treatment meets main goal in late‑stage study
• Positive Sentiment: Compass announced it will report new clinical data from two ongoing Phase 3 trials (COMP005 and COMP006) and provided a timeline for additional Phase 3 results, reinforcing near‑term news flow that supports further upside. Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
• Positive Sentiment: Market activity shows heightened bullish positioning: unusually large call option volume (over 10,000 calls) and extremely heavy equity volume suggest speculative and institutional buying around the trial news, which amplified the stock move. (Internal trading/activity reports)
• Neutral Sentiment: Public and media coverage (Investing.com, PharmaLetter, MSN) amplified investor attention; press coverage supports momentum but doesn’t guarantee regulatory approval or commercial success. Compass Pathways stock soars after positive Phase 3 trial results
• Neutral Sentiment: Reported short‑interest data in the filings appears erroneous (0 shares / NaN changes) and is unreliable as an indicator of bearish positioning or squeeze potential at present.
• Neutral Sentiment: Third‑party analyst commentary and forecasts (e.g., Lifesci Capital coverage) exist but are secondary to the actual trial readouts for near‑term price action. What is Lifesci Capital’s Forecast for CMPS FY2025 Earnings?
• Negative Sentiment: Compass launched a proposed $150M public offering of ADSs (and pre‑funded warrants), which can dilute existing shareholders and may cap near‑term upside despite the positive data. Investors should weigh dilution risk against trial progress. Compass Pathways Launches Proposed $150.0 Million Public Offering

COMPASS Pathways Price Performance

Shares of NASDAQ CMPS opened at $7.63 on Wednesday. COMPASS Pathways has a twelve month low of $2.25 and a twelve month high of $8.80. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 0.55. The firm has a 50-day moving average of $6.77 and a two-hundred day moving average of $5.89. The company has a market capitalization of $732.63 million, a price-to-earnings ratio of -2.81 and a beta of 1.92.

Wall Street Analyst Weigh In

CMPS has been the topic of a number of research reports. Morgan Stanley increased their price objective on shares of COMPASS Pathways from $10.00 to $11.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Compass Point set a $15.00 price target on COMPASS Pathways in a research note on Thursday, February 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of COMPASS Pathways in a report on Wednesday, January 21st. Lifesci Capital upgraded shares of COMPASS Pathways to a “strong-buy” rating in a report on Thursday, February 12th. Finally, Royal Bank Of Canada upped their price target on COMPASS Pathways from $16.00 to $21.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $16.11.

Hedge Funds Weigh In On COMPASS Pathways

A number of institutional investors have recently bought and sold shares of CMPS. Persistent Asset Partners Ltd purchased a new stake in COMPASS Pathways during the fourth quarter valued at about $38,000. Advisory Services Network LLC acquired a new stake in shares of COMPASS Pathways during the third quarter valued at approximately $41,000. China Universal Asset Management Co. Ltd. lifted its position in shares of COMPASS Pathways by 46.7% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company’s stock valued at $51,000 after acquiring an additional 5,817 shares in the last quarter. BIT Capital GmbH acquired a new position in COMPASS Pathways in the 3rd quarter worth approximately $54,000. Finally, Conservest Capital Advisors Inc. grew its position in COMPASS Pathways by 32.5% during the 2nd quarter. Conservest Capital Advisors Inc. now owns 20,363 shares of the company’s stock worth $57,000 after purchasing an additional 5,000 shares in the last quarter. Hedge funds and other institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.